Novel Targeted Therapies for Eosinophilic Disorders

Overview

Journal J Allergy Clin Immunol

Specialty Allergy & Immunology

Date 2012 Sep 1

PMID 22935585

Citations 37

Authors

Michael E Wechsler

Patricia C Fulkerson

Bruce S Bochner

Gail M Gauvreau

Gerald J Gleich

Tim Henkel

Roland Kolbeck

Sameer K Mathur

Hector Ortega

Jatin Patel

Calman Prussin

Paolo Renzi

Marc E Rothenberg

Florence Roufosse

Dagmar Simon

Hans-Uwe Simon

Andrew Wardlaw

Peter F Weller

Amy D Klion

Affiliations

Soon will be listed here.

Abstract

Hypereosinophilic syndromes (HESs) are a diverse group of conditions characterized by clinical manifestations attributable to eosinophilia and eosinophilic infiltration of tissues. HESs are chronic disorders with significant morbidity and mortality. Although the availability of targeted chemotherapeutic agents, including imatinib, has improved quality of life and survival in some patients with HESs, additional agents with increased efficacy and decreased toxicity are sorely needed. The purpose of this review is to provide an overview of eosinophil biology with an emphasis on potential targets of pharmacotherapy and to provide a summary of potential eosinophil-targeting agents, including those in development, in clinical trials, or approved for other disorders.

Citing Articles

Hypereosinophilia and Left Ventricular Thrombus: A Case Report and Literature Review.

Khachatryan A, Harutyunyan H, Psotka M, Batikyan A, Cinar T, Khorsandi M Cureus. 2024; 16(6):e61674.

PMID: 38966441 PMC: 11223752. DOI: 10.7759/cureus.61674.

HES and EGPA: Two Sides of the Same Coin.

Khoury P, Akuthota P, Kwon N, Steinfeld J, Roufosse F Mayo Clin Proc. 2023; 98(7):1054-1070.

PMID: 37419574 PMC: 10348452. DOI: 10.1016/j.mayocp.2023.02.013.

Pediatric hypereosinophilic syndrome associated with liver damage, portal vein, splenic vein and superior mesenteric vein thromboses: a case report.

Zheng H, Xu Y, Yan X, Yan Y, Ma S, Liu L BMC Pediatr. 2023; 23(1):233.

PMID: 37173706 PMC: 10176765. DOI: 10.1186/s12887-023-04014-0.

Sweet taste receptor agonists attenuate macrophage IL-1β expression and eosinophilic inflammation linked to autophagy deficiency in myeloid cells.

Lee J, Kim S, Choi G, Yi E, Park H, Choi W Clin Transl Med. 2022; 12(8):e1021.

PMID: 35988262 PMC: 9393075. DOI: 10.1002/ctm2.1021.

Recent advances of eosinophils and its correlated diseases.

Tao Z, Zhu H, Zhang J, Huang Z, Xiang Z, Hong T Front Public Health. 2022; 10:954721.

PMID: 35958837 PMC: 9357997. DOI: 10.3389/fpubh.2022.954721.

References

Klion A, Law M, Noel P, Kim Y, Haverty T, Nutman T . Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood. 2004; 103(8):2939-41. DOI: 10.1182/blood-2003-10-3620. View

Schuligoi R, Sturm E, Luschnig P, Konya V, Philipose S, Sedej M . CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases. Pharmacology. 2010; 85(6):372-82. DOI: 10.1159/000313836. View

Kim Y, Prussin C, Martin B, Law M, Haverty T, Nutman T . Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol. 2004; 114(6):1449-55. DOI: 10.1016/j.jaci.2004.08.027. View

Goedkoop A, de Rie M, Picavet D, Kraan M, Dinant H, van Kuijk A . Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res. 2004; 295(11):465-73. DOI: 10.1007/s00403-004-0450-y. View

Cools J, DeAngelo D, Gotlib J, Stover E, Legare R, Cortes J . A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348(13):1201-14. DOI: 10.1056/NEJMoa025217. View

Henderson Jr W, Chi E, Albert R, Chu S, Lamm W, Rochon Y . Blockade of CD49d (alpha4 integrin) on intrapulmonary but not circulating leukocytes inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. J Clin Invest. 1998; 100(12):3083-92. PMC: 508521. DOI: 10.1172/JCI119863. View

Garrett J, Jameson S, Thomson B, Collins M, Wagoner L, Freese D . Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol. 2003; 113(1):115-9. DOI: 10.1016/j.jaci.2003.10.049. View

Nakajima H, Sano H, Nishimura T, Yoshida S, Iwamoto I . Role of vascular cell adhesion molecule 1/very late activation antigen 4 and intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 interactions in antigen-induced eosinophil and T cell recruitment into the tissue. J Exp Med. 1994; 179(4):1145-54. PMC: 2191449. DOI: 10.1084/jem.179.4.1145. View

Waddell A, Ahrens R, Steinbrecher K, Donovan B, Rothenberg M, Munitz A . Colonic eosinophilic inflammation in experimental colitis is mediated by Ly6C(high) CCR2(+) inflammatory monocyte/macrophage-derived CCL11. J Immunol. 2011; 186(10):5993-6003. PMC: 3423906. DOI: 10.4049/jimmunol.1003844. View

10.

Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M . An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. J Pharmacol Exp Ther. 2003; 305(1):347-52. DOI: 10.1124/jpet.102.046748. View

11.

Rothenberg M, Klion A, Roufosse F, Kahn J, Weller P, Simon H . Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008; 358(12):1215-28. DOI: 10.1056/NEJMoa070812. View

12.

Castro M, Mathur S, Hargreave F, Boulet L, Xie F, Young J . Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011; 184(10):1125-32. DOI: 10.1164/rccm.201103-0396OC. View

13.

Majeau G, Meier W, Jimmo B, Kioussis D, Hochman P . Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol. 1994; 152(6):2753-67. View

14.

Djukanovic R, Wilson S, Kraft M, Jarjour N, Steel M, Chung K . Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004; 170(6):583-93. DOI: 10.1164/rccm.200312-1651OC. View

15.

Simon D, Wittwer J, Kostylina G, Buettiker U, Simon H, Yawalkar N . Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol. 2008; 122(2):423-4. DOI: 10.1016/j.jaci.2008.06.010. View

16.

Wenzel S, Wilbraham D, Fuller R, Burmeister Getz E, Longphre M . Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007; 370(9596):1422-31. DOI: 10.1016/S0140-6736(07)61600-6. View

17.

Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A . Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. 2009; 15(1):368-73. PMC: 4822510. DOI: 10.1158/1078-0432.CCR-08-1302. View

18.

Fulkerson P, Fischetti C, McBride M, Hassman L, Hogan S, Rothenberg M . A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. Proc Natl Acad Sci U S A. 2006; 103(44):16418-23. PMC: 1637597. DOI: 10.1073/pnas.0607863103. View

19.

Zimmermann N, McBride M, Yamada Y, Hudson S, Jones C, Cromie K . Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. Allergy. 2008; 63(9):1156-63. PMC: 2726770. DOI: 10.1111/j.1398-9995.2008.01709.x. View

20.

Ahrens R, Waddell A, Seidu L, Blanchard C, Carey R, Forbes E . Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. J Immunol. 2008; 181(10):7390-9. PMC: 2728352. DOI: 10.4049/jimmunol.181.10.7390. View